Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

by Cancer Network
0 Comments
0 Mins
The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with frontline recurrent or metastatic head and neck squamous cell carcinoma.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
Friday Plans Reviews (2025): Should You Get Friday Plans? An Honest Look at Friday Plans Pills
Next Post
Celebs Warn: Why Black Women Face Higher Uterine Fibroid Risks
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago